BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 28740384)

  • 1. Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA.
    Wang T; Yu X; Han L; Liu T; Liu Y; Zhang N
    Int J Nanomedicine; 2017; 12():4773-4788. PubMed ID: 28740384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44-Targeted Hyaluronic Acid-Coated Redox-Responsive Hyperbranched Poly(amido amine)/Plasmid DNA Ternary Nanoassemblies for Efficient Gene Delivery.
    Gu J; Chen X; Ren X; Zhang X; Fang X; Sha X
    Bioconjug Chem; 2016 Jul; 27(7):1723-36. PubMed ID: 27311558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-assembled pH-responsive hyaluronic acid-g-poly((L)-histidine) copolymer micelles for targeted intracellular delivery of doxorubicin.
    Qiu L; Li Z; Qiao M; Long M; Wang M; Zhang X; Tian C; Chen D
    Acta Biomater; 2014 May; 10(5):2024-35. PubMed ID: 24365705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment.
    Zhang X; Zhao M; Cao N; Qin W; Zhao M; Wu J; Lin D
    Biomater Sci; 2020 Mar; 8(7):1885-1896. PubMed ID: 32022813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy.
    Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y
    Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(ε-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA.
    Davoodi P; Srinivasan MP; Wang CH
    Acta Biomater; 2016 Jul; 39():79-93. PubMed ID: 27154500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free Adriamycin-Loaded pH/Reduction Dual-Responsive Hyaluronic Acid-Adriamycin Prodrug Micelles for Efficient Cancer Therapy.
    Yin T; Wang Y; Chu X; Fu Y; Wang L; Zhou J; Tang X; Liu J; Huo M
    ACS Appl Mater Interfaces; 2018 Oct; 10(42):35693-35704. PubMed ID: 30259743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin.
    Liao J; Zheng H; Fei Z; Lu B; Zheng H; Li D; Xiong X; Yi Y
    Int J Biol Macromol; 2018 Jul; 113():737-747. PubMed ID: 29505869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
    Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
    Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction/pH dual-sensitive PEGylated hyaluronan nanoparticles for targeted doxorubicin delivery.
    Xu M; Qian J; Suo A; Wang H; Yong X; Liu X; Liu R
    Carbohydr Polym; 2013 Oct; 98(1):181-8. PubMed ID: 23987334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery.
    Hang C; Zou Y; Zhong Y; Zhong Z; Meng F
    Colloids Surf B Biointerfaces; 2017 Oct; 158():547-555. PubMed ID: 28743090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme and Thermal Dual Responsive Amphiphilic Polymer Core-Shell Nanoparticle for Doxorubicin Delivery to Cancer Cells.
    Kashyap S; Singh N; Surnar B; Jayakannan M
    Biomacromolecules; 2016 Jan; 17(1):384-98. PubMed ID: 26652038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retro-inverso d-peptide-modified hyaluronic acid/bioreducible hyperbranched poly(amido amine)/pDNA core-shell ternary nanoparticles for the dual-targeted delivery of short hairpin RNA-encoding plasmids.
    Gu J; Chen X; Fang X; Sha X
    Acta Biomater; 2017 Jul; 57():156-169. PubMed ID: 28442415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
    Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
    Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endosomal pH-Responsive Fe-Based Hyaluronate Nanoparticles for Doxorubicin Delivery.
    Bae Y; Kim Y; Lee ES
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34200716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic Acid-Bilirubin Nanoparticles as a Tumor Microenvironment Reactive Oxygen Species-Responsive Nanomedicine for Targeted Cancer Therapy.
    Lee S; Lee SA; Shinn J; Lee Y
    Int J Nanomedicine; 2024; 19():4893-4906. PubMed ID: 38828202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.